^
    28d
    A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=12, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | Phase classification: P1a/1b --> P1 | N=48 --> 12
    Trial completion • Phase classification • Enrollment change • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression
    |
    Tyvyt (sintilimab) • IBI360
    almost3years
    A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=48, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression
    |
    Tyvyt (sintilimab) • IBI360
    3years
    A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=48, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression
    |
    Tyvyt (sintilimab) • IBI360